Osteoporozda Komorbiditeler*

ATA, Ayşe Merve; Gokce Kutsal, F. Yesim

Osteoporozda Komorbiditeler*

Ayşe Merve ATA, (Hacettepe Üniversitesi, Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Ankara, Türkiye)

Yeşim Gökçe KUTSAL (Hacettepe Üniversitesi, Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Ankara, Türkiye)

STED/Sürekli Tıp Eğitimi Dergisi

4 0

Yıl: 2015 Cilt: 24 Sayı: 5 Sayfa Aralığı: 185 - 190 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Osteoporozda Komorbiditeler*

Öz:

Giriş: Osteoporozlu hastalarda geniş bir yelpazeye yayılabilen komorbiditeler osteoporozun tedavisini sıklıkla olumsuz etkilemekte, hekimler ve hastalar öncelikle sistemik komorbiditelere odaklanıp başlangıçta klinik olarak sessiz seyreden osteoporoz hastalığının tanısını ve tedavisini göz ardı veya ihmal edebilmektedirler. Amaç:Bu çalışmada amaç; Hacettepe Üniversitesi Tıp Fakültesi Fiziksel Tıp ve Rehabilitasyon Kliniğine yatarak tedavi programına alınan ve osteoporoz tanısı almış olan hastalarda komorbidite varlığını araştırmaktır. Gereç ve Yöntem: Hacettepe Üniversitesi Girişimsel Olmayan Klinik Araştırmalar Etik Kurul onayını takiben; 2003-2013 yılları arasında Hacettepe Üniversitesi Tıp Fakültesi Fiziksel Tıp ve Rehabilitasyon Kliniğine yatarak tedavi programına alınan 2445 hasta retrospektif olarak tarandı. 502 hastaya Dual Enerji X Işını Dansitometri ile kemik mineral yoğunluğu ölçümü yapıldığı tespit edildi. Bu hastalardan T- skoru Dünya Sağlık Örgütü tanımlamasına göre ≤-2,5 olanlar osteoporoz olarak kabul edildi. Osteoporoz hastalarının elektronik veri tabanları kullanılarak epikriz bilgilerinden yaş, cinsiyet, vücut kitle indeksi ve osteoporoza eşlik eden komorbid hastalıkları kaydedildi ve 16-94 yaş arasındaki 190 hasta çalışma kapsamına alındı. Bulgular: Hastaların ortalama yaşı 69.38±13.53 (16-94), boy uzunluğu 158.47±9.27 (129-205), kilosu 69.09±13.46 (42-120), vücut kitle indeksi 27.60±5.45 (17.3-50.6) olarak hesaplandı. Altmış beş yaş altı 53 (ortalama yaş: 51.1), 65 yaş ve üstü 137 (ortalama yaş: 76.0) hasta bulunmaktaydı. Hastaların 152si (%80) kadın, 38i (%20) erkekti. Osteoporoz tanısı almış olan, 65 yaş ve üzeri hastalarda %30.6 sıklığında, 65 yaş altında ise %13.2 sıklığında, dört ve üzerinde komorbid hastalık bulunmaktaydı. En sık görülen komorbidite hipertansiyon olarak tespit edildi. Bunu hiperlipidemi, diabetes mellitus, koroner arter hastalığı, kronik obstrüktif pulmoner hastalık, serebrovasküler hastalık, hipotiroidi, total abdominal histerektomi ve bilateral salfingoferektomi, total diz ve kalça artroplastisi takip etmekteydi. Sonuç: Bir ya da daha fazla komorbiditesi olan hastalar birincil ve ikincil osteoporoz açısından sıkı takip edilmeli ve detaylı risk hesaplaması yapılmalıdır. Sadece koruyucu yaklaşımlar değil, erken tanı ve etkin tedavi de göz önünde tutulmalı, hastaların tedavileri, komorbiditeleri göz önüne alınarak; hasta uyumunu önceleyecek şekilde düzenlenmelidir

Anahtar Kelime:

Konular: Tıbbi Araştırmalar Deneysel

Co-morbidities in Osteoporosis

Öz:

Background: In patients with osteoporosis may spread to a wide range of co-morbidities often adversely affecting the treatment of osteoporosis. Physicians and patients primarily focus on systemic co-morbidities and they can easily be able to neglect or underestimate the diagnosis and treatment of osteoporosis which is initially characterized as a clinically silent disease. Objective: The aim of this study is, to investigate the presence of co-morbidities in inpatients who were diagnosed as osteoporosis in Hacettepe University Faculty of Medicine, Department of Physical Medicine and Rehabilitation. Materials and Methods: After the approval of the Hacettepe University Clinical Ethics Committee, medical records of 2445 cases admitted to Department of Physical Medicine and Rehabilitation from the electronic data base were retrospectively analyzed between the years of 2003- 2013. Bone mineral density measurement with Dual Energy X-Ray Densitometry were performed in 502 patients. Of these, 190 patients between the ages of 16-94 were diagnosed as osteoporosis, as defined by the World Health Organization T-score ≤-2.5 and they were studied to record their age, gender, body mass index and presence of comorbid diseases. Results: Mean age of the patients was 69.38±13.53 years (range 16-94). Where mean results for height, weight and body mass index were 158.47±9.27 cm (129-205), 69.09±13.46 kg (42-120) and 27.60±5.45 (17.3-50.6) respectively. There were 53 patients under 65 years (mean age: 51.1) and 137 patients 65 years and over (mean age 76.0). Of these patients, 152 were females (80%) and 32 were males (20%). It was found that; the osteoporotic patients who were over 65, had 30.6% and the ones under 65, had 13.2%, four or more co-morbid diseases. The most common co-morbidity was found to be hypertension. It was followed by hyperlipidemia, diabetes mellitus, coronary artery disease, chronic obstructive pulmonary disease, cerebrovascular accident, hypothyroidism, total abdominal hysterectomy and bilateral salphingoopherectomy, total knee and hip arthroplasty. Conclusion: Patients with one or more co-morbidities should be followed strictly in terms of primary or secondary osteoporosis and detailed risk calculation should be done. Not only the preventive measures, but early diagnosis and effective treatment should be taken account seriously as well. Treatment recommendations for the patients with several co-morbidities must employ strategies taking patient compliance into account.

Anahtar Kelime:

Konular: Tıbbi Araştırmalar Deneysel

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. National Osteoporosis Foundation. Clinicians Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2010 pp:2-10. Available from: http://nof.org/files/nof/public/content/file/ 344/upload/159.pdf Accessed: 1.7.2014.
2. OMalley CD1, Tran N, Zapalowski C, Daizadeh N, Olenginski TP, Cauley JA; Multimorbidity in women with and without osteoporosis: results from a large US retrospective cohort study 2004-2009. Osteoporos Int. 2014 Aug;25(8):2117-30.
3. David C, Confavreux CB, Mehsen N, Paccou J, Leboime A, Legrand E; Severity of osteoporosis: what is the impact of co-morbidities? Joint Bone Spine. 2010 Dec 77 Suppl 2:S103-6.
4. Pasoto SG, Yoshihara LA, Maeda LC, Bernik MM, Lotufo PA, Bonfa E, Pereira RM.Osteoporotic hip fractures in non-elderly patients: relevance of associated co-morbidities. Rheumatol Int. 2012 Oct;32(10):3149-53.
5. Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Senocak M, Johansson H, Kanis JA; Turkish Osteoporosis Society; Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study. Osteoporos Int. 2012 Mar;23(3):949-55.
6. Giangregorio L, Jantzi M, Papaioannou A, Hirdes J, Maxwell CJ, Poss JW; Osteoporosis management among residents living in long-term care. Osteoporos Int. 2009 Sep;20(9):1471-8.
7. Vik SA, Jantzi M, Poss J, Hirdes J, Hanley DA, Hogan DB, Maxwell CJ; Factors associated with pharmacologic treatment of osteoporosis in an older home care population. J Gerontol A Biol Sci Med Sci. 2007 Aug;62(8):872-8.
8. M. Fortin, H. Soubhi, C. Hudon, E. A. Bayliss, and M. van den Akker, Multimorbiditys many challenges, The British Medical Journal, 2007; 334 (7602): 10161017.
9. Gokçe Kutsal Y, Savaş S, İnanıcı F, Özdemir O. et al. The Frequency of the Clinical Risk Factors in Postmenopausal Osteoporosis. Turk J Rheumatol 2013;28(4):256-62.
10. J. F. Orueta, R. Nuno-Solinıs, A. Garcıa-Alvarez, and E. AlonsoMoran,Prevalence of multimorbidity according to the deprivation level among the elderly in the Basque Country, BMC Public Health, 2013; 13, article: 918.
11. Nuño-Solinis R1, Rodríguez-Pereira C1, AlonsoMorán E1, Orueta JF2. Comorbidity and healthcare expenditure in women with osteoporosis living in the basque country (Spain). J Osteoporos. 2014;2014:205954. Available at http://www.ncbi.nlm.nih.gov/pmc/articles /PMC4202277/ Accessed 10.12.2014
12. Alkan BM, Fidan F, Tosun A, Ardıçoğlu Ö;Fiziksel Tıp ve Rehabilitasyon Polikliniğimize Başvuran Hastalarda Osteoporoz İnsidansı. Türk Osteoporoz Dergisi. 2011;17:10-3.
13. Chen LT1, Lee JA, Chua BS, Howe TS; Hip fractures in the elderly: the impact of comorbid illnesses on hospitalisation costs. Ann Acad Med Singapore. 2007 Sep;36(9):784-7.
14. Dennison EM, Compston JE, Flahive J, Siris ES, Gehlbach SH, Adachi JD, Boonen S, Chapurlat R, Díez-Pérez A, Anderson FA Jr, Hooven FH, LaCroix AZ, Lindsay R, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Saag KG, Sambrook P, Silverman S, Watts NB, Greenspan SL, Premaor M, Cooper C; GLOW Investigators; Effect of comorbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2012 Jun;50(6):1288-93.
15. den Uyl D, Nurmohamed MT, van Tuyl LH, Raterman HG, Lems WF; (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res Ther. 2011 Jan 17;13(1):R5.
16. Fisher A, Srikusalanukul W, Davis M, Smith P. Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links. Clin Interv Aging. 2013;8:239-56.
17. Kalkan İH, Suher M, Koç E; Hiperlipidemi Osteoporoz İlişkisi. Türk Osteoporoz Dergisi 2006; 12 (1):1-4.
18. Yamaguchi T., Sugimoto T., Yano S., Yamauchi M., Sowa H., Chen Q., Chihara K. Plasma lipids and osteoporosis in postmenopausal women. Endocr. J.2002; 49, 211-7.
19. Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP; LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science. 2007 Mar 2;315(5816):1278- 82.
20. Isidro ML1, Ruano B; Bone disease in diabetes. Curr Diabetes Rev. 2010 May;6(3):144-55.
21. Kanazawa I, Sugimoto T.Bone diseases caused by impaired glucose and lipid metabolism]. Clin Calcium. 2013 Nov;23(11):1605-11.
22. Altınova AE, Yetkin İ; Diabetes Mellitus ve Osteoporoz. Türk Osteoporoz Dergisi 2011;17:96- 9.
23. Knopp-Sihota JA, Cummings GG, Newburn-Cook CV, Homik J, Voaklander DDementia diagnosis and osteoporosis treatment propensity: a populationbased nested case-control study. Geriatr Gerontol Int. 2014 Jan;14(1):121-9.
24. Dennison E. Acknowledgment of comorbidities could improve fracture prediction algorithms. Bone. 2012. Available from: http://www.healio.com/endocrinology/bonemineral-metabolism/news/print/endocrinetoday/%7B50c8a508-a67a-4009-b978- b78e2560be9f%7D/acknowledgment-ofcomorbidities-could-improve-fracture-predictionalgorithms. Accessed: 1.7.2014.

APA	ATA A, Gokce Kutsal F (2015). Osteoporozda Komorbiditeler*. , 185 - 190.
Chicago	ATA Ayşe Merve,Gokce Kutsal F. Yesim Osteoporozda Komorbiditeler*. (2015): 185 - 190.
MLA	ATA Ayşe Merve,Gokce Kutsal F. Yesim Osteoporozda Komorbiditeler*. , 2015, ss.185 - 190.
AMA	ATA A,Gokce Kutsal F Osteoporozda Komorbiditeler*. . 2015; 185 - 190.
Vancouver	ATA A,Gokce Kutsal F Osteoporozda Komorbiditeler*. . 2015; 185 - 190.
IEEE	ATA A,Gokce Kutsal F "Osteoporozda Komorbiditeler*." , ss.185 - 190, 2015.
ISNAD	ATA, Ayşe Merve - Gokce Kutsal, F. Yesim. "Osteoporozda Komorbiditeler*". (2015), 185-190.

APA	ATA A, Gokce Kutsal F (2015). Osteoporozda Komorbiditeler*. STED/Sürekli Tıp Eğitimi Dergisi, 24(5), 185 - 190.
Chicago	ATA Ayşe Merve,Gokce Kutsal F. Yesim Osteoporozda Komorbiditeler*. STED/Sürekli Tıp Eğitimi Dergisi 24, no.5 (2015): 185 - 190.
MLA	ATA Ayşe Merve,Gokce Kutsal F. Yesim Osteoporozda Komorbiditeler*. STED/Sürekli Tıp Eğitimi Dergisi, vol.24, no.5, 2015, ss.185 - 190.
AMA	ATA A,Gokce Kutsal F Osteoporozda Komorbiditeler*. STED/Sürekli Tıp Eğitimi Dergisi. 2015; 24(5): 185 - 190.
Vancouver	ATA A,Gokce Kutsal F Osteoporozda Komorbiditeler*. STED/Sürekli Tıp Eğitimi Dergisi. 2015; 24(5): 185 - 190.
IEEE	ATA A,Gokce Kutsal F "Osteoporozda Komorbiditeler*." STED/Sürekli Tıp Eğitimi Dergisi, 24, ss.185 - 190, 2015.
ISNAD	ATA, Ayşe Merve - Gokce Kutsal, F. Yesim. "Osteoporozda Komorbiditeler*". STED/Sürekli Tıp Eğitimi Dergisi 24/5 (2015), 185-190.